32996 Federal Register / Vol. 87, No. 105 / Wednesday, June 1, 2022 / Rules and Regulations 

conducted pursuant to the provisions of 

5 U.S.C. 556 and 557. The CSA sets 

forth the procedures and criteria for 

scheduling a drug or other substance. 

Such actions are exempt from review by 

the Office of Management and Budget 

(OMB) pursuant to section 3(d)(1) of 

Executive Order (E.O.) 12866 and the 

principles reaffirmed in E.O. 13563. 

Executive Order 12988, Civil Justice 

Reform 

This regulation meets the applicable 

standards set forth in sections 3(a) and 

3(b)(2) of E.O. 12988 to eliminate 

drafting errors and ambiguity, minimize 

litigation, provide a clear legal standard 

for affected conduct, and promote 

simplification and burden reduction. 

Executive Order 13132, Federalism 

This rulemaking does not have 

federalism implications warranting the 

application of E.O. 13132. The rule does 

not have substantial direct effects on the 

States, on the relationship between the 

national government and the States, or 

on the distribution of power and 

responsibilities among the various 

levels of government. 

Executive Order 13175, Consultation 

and Coordination With Indian Tribal 

Governments 

This rule does not have tribal 

implications warranting the application 

of E.O. 13175. It does not have 

substantial direct effects on one or more 

Indian tribes, on the relationship 

between the Federal government and 

Indian tribes, or on the distribution of 

power and responsibilities between the 

Federal government and Indian tribes. 

Regulatory Flexibility Act 

The Regulatory Flexibility Act (RFA) 

(5 U.S.C. 601–612) applies to rules that 

are subject to notice and comment 

under section 553(b) of the APA. As 

noted in the above discussion regarding 

the applicability of the APA, DEA is not 

required to publish a general notice of 

proposed rulemaking. Consequently, the 

RFA does not apply to this IFR. 

Unfunded Mandates Reform Act of 1995 

In accordance with the Unfunded 

Mandates Reform Act (UMRA) of 1995, 

2 U.S.C. 1501 et seq., DEA has 

determined that this action would not 

result in any Federal mandate that may 

result ‘‘in the expenditure by State, 

local, and tribal governments, in the 

aggregate, or by the private sector, of 

$100,000,000 or more (adjusted 

annually for inflation) in any 1 year.’’ 

Therefore, neither a Small Government 

Agency Plan nor any other action is 

required under UMRA of 1995. 

Paperwork Reduction Act of 1995 

This action does not impose a new 

collection of information requirement 

under the Paperwork Reduction Act of 

1995. 44 U.S.C. 3501–3521. This action 

would not impose recordkeeping or 

reporting requirements on State or local 

governments, individuals, businesses, or 

organizations. An agency may not 

conduct or sponsor, and a person is not 

required to respond to, a collection of 

information unless it displays a 

currently valid OMB control number. 

Congressional Review Act 

This rule is not a major rule as 

defined by the Congressional Review 

Act (CRA), 5 U.S.C. 804. However, 

pursuant to the CRA, DEA is submitting 

a copy of this IFR to both Houses of 

Congress and to the Comptroller 

General. 

List of Subjects in 21 CFR Part 1308 

Administrative practice and 

procedure, Drug traffic control, 

Reporting and recordkeeping 

requirements. 

For the reasons set out above, DEA 

amends 21 CFR part 1308 as follows: 

PART 1308—SCHEDULES OF 

CONTROLLED SUBSTANCES 

■ 1. The authority citation for 21 CFR 

part 1308 continues to read as follows: 

Authority: 21 U.S.C. 811, 812, 871(b), 

956(b) unless otherwise noted. 

■ 2. In § 1308.15: 

■ a. Redesignate paragraphs (e)(4) 

through (6) as paragraphs (e)(5) through 

(7); and 

■ b. Add new paragraph (e)(4). 

The addition reads as follows: 

§ 1308.15 Schedule V. 

* * * * * 

(e) * * * 

(4) Ganaxolone (3a-hydroxy-3b-methyl-5a-pregnan-20-one) ........................................................................................................... 2401 

* * * * * 

Anne Milgram, 

Administrator. 

[FR Doc. 2022–11735 Filed 5–31–22; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

21 CFR Part 1308 

[Docket No. DEA–495] 

Schedules of Controlled Substances: 

Placement of N-Ethylhexedrone, alphaPyrrolidinohexanophenone, 4-Methylalpha-ethylaminopentiophenone, 4′- 

Methyl-alphapyrrolidinohexiophenone, alphaPyrrolidinoheptaphenone, and 4′- 

Chloro-alphapyrrolidinovalerophenone in Schedule 

I 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Final rule. 

SUMMARY: By this rule, the Drug 

Enforcement Administration 

permanently places six synthetic 

cathinones, as identified in this rule, in 

schedule I of the Controlled Substances 

Act. These six substances are currently 

listed in schedule I pursuant to a 

temporary scheduling order. As a result 

of this rule, the regulatory controls and 

administrative, civil, and criminal 

sanctions applicable to schedule I 

controlled substances on persons who 

handle (manufacture, distribute, reverse 

distribute, import, export, engage in 

research, conduct instructional 

activities or chemical analysis, or 

possess) or propose to handle these six 

specified controlled substances will 

continue to apply. 

DATES: Effective June 1, 2022. 

FOR FURTHER INFORMATION CONTACT: 

Terrence L. Boos, Drug and Chemical 

Evaluation Section, Diversion Control 

Division, Drug Enforcement 

Administration; Telephone: (571) 362– 

8207. 

SUPPLEMENTARY INFORMATION: In this 

rule, the Drug Enforcement 

Administration (DEA) is permanently 


jspears on DSK121TN23PROD with RULES1
Federal Register / Vol. 87, No. 105 / Wednesday, June 1, 2022 / Rules and Regulations 32997 

1As discussed in a memorandum of 

understanding entered into by the Food and Drug 

Administration (FDA) and the National Institute on 

Drug Abuse (NIDA), FDA acts as the lead agency 

within HHS in carrying out the Secretary’s 

scheduling responsibilities under the CSA, with the 

concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. 

The Secretary of HHS has delegated to the Assistant 

Secretary for Health of HHS the authority to make 

domestic drug scheduling recommendations. 58 FR 

35460, July 1, 1993. 

2 In addition to a-ethylaminohexanophenone and 

2-(ethylamino)-1-phenylhexan-1-one, the NPRM 

preamble provided two other names (ethyl 

hexedrone and HEXEN). 

3N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, 

PV8, and 4-chloro-a-PVP have been subject to 

schedule I controls on a temporary basis, pursuant 

to 21 U.S.C. 811(h), by virtue of the temporary 

scheduling order (84 FR 34291, July 18, 2019) and 

the subsequent one year extension of that order (86 

FR 37672, July 16, 2021). 

scheduling the following six controlled 

substances, including their optical, 

positional, and geometric isomers, salts, 

and salts of isomers whenever the 

existence of such salts, isomers, and 

salts of isomers is possible within the 

specific chemical designation, in 

schedule I of the Controlled Substances 

Act (CSA): 

• N-ethylhexedrone (other names: aethylaminohexanophenone, 2- 

(ethylamino)-1-phenylhexan-1-one), 

• alpha-pyrrolidinohexanophenone 

(other names: a-PHP, apyrrolidinohexanophenone, 1-phenyl-2- 

(pyrrolidin-1-yl)hexan-1-one), 

• 4-methyl-alphaethylaminopentiophenone (other names: 

4-MEAP, 2-(ethylamino)-1-(4- 

methylphenyl)pentan-1-one), 

• 4′-methyl-alphapyrrolidinohexiophenone (other names: 

MPHP, 4′-methyl-alphapyrrolidinohexanophenone, 1-(4- 

methylphenyl)-2-(pyrrolidin-1-yl)hexan1-one), 

• alpha-pyrrolidinoheptaphenone 

(other names: PV8, 1-phenyl-2- 

(pyrrolidin-1-yl)heptan-1-one), and 

• 4′-chloro-alphapyrrolidinovalerophenone (other names: 

4-chloro-a-PVP, 4′-chloro-apyrrolidinopentiophenone, 1-(4- 

chlorophenyl)-2-(pyrrolidin-1- 

yl)pentan-1-one). 

Legal Authority 

The CSA provides that proceedings 

for the issuance, amendment, or repeal 

of the scheduling of any drug or other 

substance may be initiated by the 

Attorney General: (1) On his own 

motion; (2) at the request of the 

Secretary of the Department of Health 

and Human Services (HHS); 1 or (3) on 

the petition of any interested party. 21 

U.S.C. 811(a). This action was initiated 

on the Attorney General’s own motion, 

as delegated to the Administrator of the 

Drug Enforcement Administration 

(DEA), and is supported by, inter alia, 

a recommendation from the Assistant 

Secretary for Health of HHS (Assistant 

Secretary) and an evaluation of all other 

relevant data by DEA. The regulatory 

controls and administrative, civil, and 

criminal sanctions for schedule I 

controlled substances on any person 

who handles or proposes to handle Nethylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, or 4-chloro-a-PVP will 

continue to apply as a result of this 

action. 

Background 

The subject substances of this final 

rule are currently controlled in schedule 

I of the CSA by virtue of a temporary 

scheduling order (84 FR 34291, July 18, 

2019) and an extension of that order (86 

FR 37672, July 16, 2021). On July 16, 

2021, pursuant to 21 U.S.C. 811(a), DEA 

published a notice of proposed 

rulemaking (NPRM) to permanently 

control these six synthetic cathinones in 

schedule I of the CSA. 86 FR 37719. 

NPRM 

DEA’s July 2021 rule proposed to 

permanently control N-ethylhexedrone, 

a-PHP, 4-MEAP, MPHP, PV8, and 4- 

chloro-a-PVP, and their optical, 

positional, and geometric isomers, salts, 

and salts of isomers in schedule I of the 

CSA. Specifically, DEA proposed to add 

these six synthetic cathinones to the 

hallucinogenic substances list under 21 

CFR 1308.11(d)(94) through (99), 

respectively. The proposed regulatory 

text provided name(s) for these six 

substances as follows: 

• N-ethylhexedrone (other name: aethylaminohexanophenone), 

• alpha-pyrrolidinohexanophenone 

(other names: a-PHP, a-pyrrolidinohexanophenone, 1-phenyl-2-(pyrrolidin1-yl)hexan-1-one), 

• 4-methyl-alphaethylaminopentiophenone (other names: 

4-MEAP, 2-(ethylamino)-1-(4- 

methylphenyl)pentan-1-one), 

• 4′-methyl-alphapyrrolidinohexiophenone (other names: 

MPHP, 4-methyl-alpha-pyrrolidino 

hexanophenone,, 1-(4-methylphenyl)-2- 

(pyrrolidin-1-yl)hexan-1-one), 

• alpha-pyrrolidinoheptaphenone 

(other names: PV8, 1-phenyl-2- 

(pyrrolidin-1-yl)heptan-1-one), and 

• 4′-chloro-alphapyrrolidinovalerophenone (other names: 

4-chloro-a-PVP, 4-chloro-apyrrolidinopentiophenone, 1-(4- 

chlorophenyl)-2-(pyrrolidin-1- 

yl)pentan-1-one). 

Regarding the substance Nethylhexedrone, the preamble 

(Supplementary Information section) for 

the NPRM provided aethylaminohexanophenone as well as 

multiple other names, including 2- 

(ethylamino)-1-phenylhexan-1-one.2

The NPRM provided an opportunity 

for interested persons to file a request 

for hearing in accordance with DEA 

regulations on or before August 16, 

2021. No requests for such a hearing 

were received by DEA. The NPRM also 

provided an opportunity for interested 

persons to submit comments on the 

proposed rule on or before August 16, 

2021. DEA did not receive any 

comments. 

Determination for Permanent 

Scheduling 

Based on the rationale set forth in the 

NPRM, the Administrator makes the 

findings, required under 21 U.S.C. 

811(a) and 812(b)(1), for permanent 

placement of N-ethylhexedrone, a-PHP, 

4-MEAP, MPHP, PV8, and 4-chloro-aPVP, including their salts, isomers, and 

salts of isomers whenever the existence 

of such salts, isomers, and salts of 

isomers is possible within the specific 

chemical designation, in schedule I of 

the CSA. This final rule adds the six 

substances to the hallucinogenic 

substances list under 21 CFR 

1308.11(d), and maintains their 

placement in schedule I. This final rule 

provides the same other names for all 

six specific substances, used in the 

regulatory text of the NPRM. In 

addition, this rule adds one other name, 

2-(ethylamino)-1-phenylhexan-1-one, 

for the substance N-ethylhexedrone. As 

discussed above, this additional other 

name was provided in the preamble for 

the NPRM. 

Requirements for Handling NEthylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, and 4-Chloro-a-PVP 

N-Ethylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, or 4-chloro-a-PVP will 

continue 3 to be subject to the CSA’s 

schedule I regulatory controls and 

administrative, civil, and criminal 

sanctions applicable to the manufacture, 

distribution, reverse distribution, 

importation, exportation, research, and 

conduct of instructional activities 

involving the handling of schedule I 

controlled substances including the 

following: 

1. Registration. Any person who 

handles (manufactures, distributes, 

reverse distributes, imports, exports, 

engages in research, or conducts 

instructional activities or chemical 

analysis with, or possesses) or who 

desires to handle N-ethylhexedrone, aPHP, 4-MEAP, MPHP, PV8, or 4-chloroa-PVP must be registered with DEA to 


jspears on DSK121TN23PROD with RULES1
32998 Federal Register / Vol. 87, No. 105 / Wednesday, June 1, 2022 / Rules and Regulations 

conduct such activities pursuant to 21 

U.S.C. 822, 823, 957, and 958, and in 

accordance with 21 CFR parts 1301 and 

1312. 

2. Security. N-Ethylhexedrone, a-PHP, 

4-MEAP, MPHP, PV8, and 4-chloro-aPVP are subject to schedule I security 

requirements and must be handled and 

stored pursuant to 21 U.S.C. 823 and in 

accordance with 21 CFR 1301.71– 

1301.76. Non-practitioners handling Nethylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, or 4-chloro-a-PVP must 

also comply with the employee 

screening requirements of 21 CFR 

1301.90–1301.93. 

3. Labeling and Packaging. All labels, 

labeling, and packaging for commercial 

containers of N-ethylhexedrone, a-PHP, 

4-MEAP, MPHP, PV8, and 4-chloro-aPVP must be in compliance with 21 

U.S.C. 825, and be in accordance with 

21 CFR part 1302. 

4. Quota. Only registered 

manufacturers are permitted to 

manufacture N-ethylhexedrone, a-PHP, 

4-MEAP, MPHP, PV8, or 4-chloro-a-PVP 

in accordance with a quota assigned 

pursuant to 21 U.S.C. 826 and in 

accordance with 21 CFR part 1303. 

5. Inventory. Every DEA registrant 

who possesses any quantity of Nethylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, or 4-chloro-a-PVP was 

required to keep an inventory of all 

stocks of these substances on hand as of 

July 18, 2019, pursuant to 21 U.S.C. 827 

and 958 and in accordance with 21 CFR 

1304.03, 1304.04, and 1304.11(a) and 

(d). 

6. Records and Reports. DEA 

registrants must maintain records and 

submit reports with respect to Nethylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, or 4-chloro-a-PVP pursuant 

to 21 U.S.C. 827 and 958(e), and in 

accordance with 21 CFR 1301.74(b) and 

(c) and parts 1304, 1312, and 1317. 

Manufacturers and distributors must 

submit reports regarding these 

substances to the Automation of Reports 

and Consolidated Order System 

pursuant to 21 U.S.C. 827 and in 

accordance with 21 CFR parts 1304 and 

1312. 

7. Order Forms. Every DEA registrant 

who distributes N-ethylhexedrone, aPHP, 4-MEAP, MPHP, PV8, or 4-chloroa-PVP must continue to comply with 

the order form requirements, pursuant 

to 21 U.S.C. 828 and in accordance with 

21 CFR part 1305. 

8. Importation and Exportation. All 

importation and exportation of Nethylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, or 4-chloro-a-PVP must 

continue to be in compliance with 21 

U.S.C. 952, 953, 957, and 958, and in 

accordance with 21 CFR part 1312. 

9. Liability. Any activity involving Nethylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, or 4-chloro-a-PVP not 

authorized by, or in violation of the CSA 

or its implementing regulations, is 

unlawful, and may subject the person to 

administrative, civil, and/or criminal 

sanctions. 

Regulatory Analyses 

Executive Orders 12866 (Regulatory 

Planning and Review) and 13563 

(Improving Regulation and Regulatory 

Review) 

In accordance with 21 U.S.C. 811(a), 

this scheduling action is subject to 

formal rulemaking procedures 

performed ‘‘on the record after 

opportunity for a hearing,’’ which are 

conducted pursuant to the provisions of 

5 U.S.C. 556 and 557. The CSA sets 

forth the criteria for scheduling a drug 

or other substance. Such actions are 

exempt from review by the Office of 

Management and Budget (OMB) 

pursuant to section 3(d)(1) of Executive 

Order (E.O.) 12866 and the principles 

reaffirmed in E.O. 13563. 

Executive Order 12988, Civil Justice 

Reform 

This regulation meets the applicable 

standards set forth in sections 3(a) and 

3(b)(2) of E.O. 12988 to eliminate 

drafting errors and ambiguity, minimize 

litigation, provide a clear legal standard 

for affected conduct, and promote 

simplification and burden reduction. 

Executive Order 13132, Federalism 

This rulemaking does not have 

federalism implications warranting the 

application of E.O. 13132. The final rule 

does not have substantial direct effects 

on the states, on the relationship 

between the national government and 

the states, or the distribution of power 

and responsibilities among the various 

levels of government. 

Executive Order 13175, Consultation 

and Coordination With Indian Tribal 

Governments 

This final rule does not have tribal 

implications warranting the application 

of E.O. 13175. It does not have 

substantial direct effects on one or more 

Indian tribes, on the relationship 

between the Federal government and 

Indian tribes, or on the distribution of 

power and responsibilities between the 

Federal government and Indian tribes. 

Regulatory Flexibility Act 

The Administrator, in accordance 

with the Regulatory Flexibility Act, 5 

U.S.C. 601–612, has reviewed this final 

rule and by approving it certifies that it 

will not have a significant economic 

impact on a substantial number of small 

entities. On July 18, 2019, DEA 

published an order to temporarily place 

N-ethylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, and 4-chloro-a-PVP in 

schedule I of the CSA pursuant to the 

temporary scheduling provisions of 21 

U.S.C. 811(h). 84 FR 34291. DEA 

estimates that all entities handling or 

planning to handle these substances 

have already established and 

implemented the systems and processes 

required to handle N-ethylhexedrone, aPHP, 4-MEAP, MPHP, PV8, or 4-chloroa-PVP. There are currently 34 unique 

registrations authorized to handle Nethylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, or 4-chloro-a-PVP 

specifically, as well as a number of 

registered analytical labs that are 

authorized to handle schedule I 

controlled substances generally. From 

review of entity names, DEA estimates 

these 34 registrations represent 29 

entities. Some of these entities are likely 

to be large entities. However, since DEA 

does not have information of registrant 

size and the majority of DEA registrants 

are small entities or are employed by 

small entities, DEA estimates a 

maximum of 29 entities are small 

entities. Therefore, DEA conservatively 

estimates as many as 29 small entities 

are affected by this proposed rule. 

A review of the 34 registrations 

indicates that all entities that currently 

handle N-ethylhexedrone, a-PHP, 4- 

MEAP, MPHP, PV8, or 4-chloro-a-PVP 

also handle other schedule I controlled 

substances, and thus they have 

established and implemented (or 

maintain) the systems and processes 

required to handle N-ethylhexedrone, aPHP, 4-MEAP, MPHP, PV8, and 4- 

chloro-a-PVP as a schedule I substance. 

Therefore, DEA anticipates that this 

final rule will impose minimal or no 

economic impact on any affected 

entities, and, thus, will not have a 

significant economic impact on any of 

the 29 affected small entities. Therefore, 

DEA has concluded that this final rule 

will not have a significant economic 

impact on a substantial number of small 

entities. 

Unfunded Mandates Reform Act of 1995 

In accordance with the Unfunded 

Mandates Reform Act (UMRA) of 1995, 

2 U.S.C. 1501 et seq., DEA has 

determined and certifies that this action 

would not result in any Federal 

mandate that may result ‘‘in the 

expenditure by State, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $100,000,000 or more 

(adjusted annually for inflation) in any 

1 year * * * .’’ Therefore, neither a 

Small Government Agency Plan nor any 


jspears on DSK121TN23PROD with RULES1
Federal Register / Vol. 87, No. 105 / Wednesday, June 1, 2022 / Rules and Regulations 32999 

other action is required under UMRA of 

1995. 

Congressional Review Act 

This rule is not a major rule as 

defined by the Congressional Review 

Act (CRA), 5 U.S.C. 804. However, 

pursuant to the CRA, DEA is submitting 

a copy of the final rule to both Houses 

of Congress and to the Comptroller 

General. 

Paperwork Reduction Act of 1995 

This action does not impose a new 

collection of information under the 

Paperwork Reduction Act of 1995. 44 

U.S.C. 3501–3521. This action would 

not impose recordkeeping or reporting 

requirements on State or local 

governments, individuals, businesses, or 

organizations. An agency may not 

conduct or sponsor, and a person is not 

required to respond to, a collection of 

information unless it displays a 

currently valid OMB control number. 

Determination To Make Rule Effective 

Immediately 

As indicated above, this rule finalizes 

the schedule I control status of Nethylhexedrone, a-PHP, 4-MEAP, 

MPHP, PV8, and 4-chloro-a-PVP that 

has already been in effect for over two 

years by virtue of the temporary 

scheduling order (84 FR 34291, July 18, 

2019) and the subsequent one year 

extension of that order (86 FR 37672, 

July 16, 2021). The July 2019 order was 

effective on the date of publication, and 

was based on findings by the thenActing Administrator that the temporary 

scheduling of these substances was 

necessary to avoid an imminent hazard 

to the public safety pursuant to 21 

U.S.C. 811(h)(1). 

Because this rule finalizes the control 

status of N-ethylhexedrone, a-PHP, 4- 

MEAP, MPHP, PV8, and 4-chloro-a-PVP 

that has already been in effect for over 

two years, it does not alter the legal 

obligations of any person who handles 

these substances. Rather, it merely 

makes permanent the current 

scheduling status and corresponding 

legal obligations. Therefore, DEA is 

making the rule effective on the date of 

publication in the Federal Register, as 

any delay in the effective date is 

unnecessary and would be contrary to 

the public interest. See 5 U.S.C. 553(d). 

List of Subjects in 21 CFR Part 1308 

Administrative practice and 

procedure, Drug traffic control, 

Reporting and recordkeeping 

requirements. 

For the reasons set out above, DEA 

amends 21 CFR part 1308 as follows: 

PART 1308—SCHEDULES OF 

CONTROLLED SUBSTANCES 

■ 1. The authority citation for part 1308 

continues to read as follows: 

Authority: 21 U.S.C. 811, 812, 871(b), 

956(b), unless otherwise noted. 

■ 2. In § 1308.11, add paragraphs (d)(94) 

through (99) and remove and reserve 

paragraphs (h)(42) through (47). 

The additions read as follows: 

§ 1308.11 Schedule I. 

* * * * * 

(d) * * * 

(94) N-Ethylhexedrone (Other names: a-ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one) ............................. 7246 

(95) alpha-Pyrrolidinohexanophenone (Other names: a-PHP; a-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1- 

yl)hexan-1-one) ............................................................................................................................................................................... 7544 

(96) 4-Methyl-alpha-ethylaminopentiophenone (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one) ..... 7245 

(97) 4′-Methyl-alpha-pyrrolidinohexiophenone (Other names: MPHP; 4′-methyl-alpha-pyrrolidinohexanophenone; 1-(4- 

methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one) ............................................................................................................................ 7446 

(98) alpha-Pyrrolidinoheptaphenone (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one) ........................................ 7548 

(99) 4′-Chloro-alpha-pyrrolidinovalerophenone (Other names: 4-chloro-a-PVP; 4′-chloro-a-pyrrolidinopentiophenone; 1-(4- 

chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one) ............................................................................................................................ 7443 

* * * * * 

Anne Milgram, 

Administrator. 

[FR Doc. 2022–11740 Filed 5–31–22; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Occupational Safety and Health 

Administration 

29 CFR Part 1910 

Occupational Safety and Health 

Standards 

CFR Correction 

This rule is being published by the 

Office of the Federal Register to correct 

an editorial or technical error that 

appeared in the most recent annual 

revision of the Code of Federal 

Regulations. 

■ In Title 29 of the Code of Federal 

Regulations, Parts 1900 to 1910.999, 

revised as of July 1, 2021, in § 1910.95, 

in section II of appendix A, remove the 

term ‘‘TWA 6.61’’ in the formula and 

add the term ‘‘TWA=16.61’’ in its place. 

[FR Doc. 2022–11613 Filed 5–31–22; 8:45 am] 

BILLING CODE 0099–10–P 

DEPARTMENT OF THE TREASURY 

Office of Foreign Assets Control 

31 CFR Part 587 

Publication of Russian Harmful 

Foreign Activities Sanctions 

Regulations Web General Licenses 7A, 

26A, 31, and 32 

AGENCY: Office of Foreign Assets 

Control, Treasury. 

ACTION: Publication of Web General 

Licenses. 

SUMMARY: The Department of the 

Treasury’s Office of Foreign Assets 

Control (OFAC) is publishing four 

general licenses (GLs) issued pursuant 

to the Russian Harmful Foreign 

Activities Sanctions Regulations: GL 7A, 

GL 26A, GL 31, and GL 32, each of 

which was previously issued on OFAC’s 

website. 

DATES: GL 7A, GL 26A, GL 31, and GL 

32 were each issued on May 5, 2022. 

See SUPPLEMENTARY INFORMATION of this 

publication for additional relevant 

dates. 

FOR FURTHER INFORMATION CONTACT: 

OFAC: Assistant Director for Licensing, 

202–622–2480; Assistant Director for 

Regulatory Affairs, 202–622–4855; or 

Assistant Director for Sanctions 

Compliance & Evaluation, 202–622– 

2490. 

SUPPLEMENTARY INFORMATION: 

Electronic Availability 

This document and additional 

information concerning OFAC are 

available on OFAC’s website: 

www.treas.gov/ofac. 

Background 

On May 5, 2022, OFAC, in 

consultation with the Department of 

State, issued pursuant to the Russian 

Harmful Foreign Activities Sanctions 


jspears on DSK121TN23PROD with RULES1